Company: GRCE
Filing Date: 2025-03-10
Form Type: S-3
Source: 0001140361-25-007769
Chunk: 25

Company: Grace Therapeutics, Inc.
Filing Date: 2025-03-10
Form: S-3
Chunk 25
---
-manipulation rules of
          Regulation M under the Exchange Act may apply to sales of the Common Stock covered by this prospectus in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies
          of this prospectus (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any
          broker-dealer that participates in transactions involving the sale of the Common Stock covered by this prospectus against certain liabilities, including liabilities arising under the Securities Act.

We have agreed to indemnify the Selling Stockholders against liabilities,
          including liabilities under the Securities Act and state securities laws, relating to the registration of the Common Stock covered by this prospectus.

We have agreed with the Selling Stockholders to use our reasonable best efforts
          to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i) the date on which the Selling Stockholders shall have resold or otherwise disposed
          of all the Common Stock covered by this prospectus and (ii) the date on which the shares of Common Stock covered by this prospectus no longer constitute “Registrable Securities” as such term is defined in the Registration Rights Agreement, such
          that they may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of
          similar effect.

<div align='center'>10</div>

#### TABLE OF CONTENTS

### LEGAL MATTERS
The validity of the shares of Common Stock offered hereby is being passed upon
          for us by Hogan Lovells US LLP.

### EXPERTS
The consolidated financial statements of the Company as of March 31, 2024, and
          for the year ended March 31, 2024, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the
          authority of said firm as experts in accounting and auditing.

Our consolidated financial statements as of and for the year ended March 31,
          2023 included in our Annual Report on Form 10-K for the year ended March 31, 2024 have been audited by Ernst